Measuring microRNA reporter activity in skeletal muscle using hydrodynamic limb vein injection of plasmid DNA combined with in vivo imaging
© Guess et al.; licensee BioMed Central Ltd. 2013
Received: 13 February 2013
Accepted: 28 May 2013
Published: 1 August 2013
microRNA regulation plays an important role in the remodeling that occurs in response to pathologic and physiologic stimuli in skeletal muscle. In response to stress, microRNAs are dynamically regulated, resulting in a widespread “fine-tuning” of gene expression. An understanding of this dynamic regulation is critical to targeting future therapeutic strategies. Experiments elucidating this dynamic regulation have typically relied on in vitro reporter assays, ex vivo sample analysis, and transgenic mouse studies. Surprisingly, no experimental method to date allows rapid in vivo analysis of microRNA activity in mammals.
To improve microRNA studies we have developed a novel reporter assay for the measurement of skeletal muscle microRNA activity in vivo. To minimize muscle damage, hydrodynamic limb vein injection was used for the introduction of plasmid DNA encoding bioluminescent and fluorescent reporters, including click-beetle luciferase and the far-red fluorescent protein mKATE. We then applied this technique to the measurement of miR-206 activity in dystrophic mdx4cv animals.
We found that hydrodynamic limb vein injection is minimally damaging to myofibers, and as a result no induction of muscle-specific miR-206 (indicative of an injury response) was detected. Unlike intramuscular injection or electroporation, we found that hydrodynamic limb vein injection results in dispersed reporter expression across multiple hindlimb muscle groups. Additionally, by utilizing click-beetle luciferase from Pyrophorus plagiophthalamus as a reporter and the far-red fluorescent protein mKATE for normalization, we show as a proof of principle that we can detect elevated miR-206 activity in mdx4cv animals when compared to C57Bl/6 controls.
Hydrodynamic limb vein injection of plasmid DNA followed by in vivo bioluminescent imaging is a novel assay for the detection of reporter activity in skeletal muscle in vivo. We believe that this method will allow for the rapid and precise detection of both transcriptional and post-transcriptional regulation of gene expression in response to skeletal muscle stress. Additionally, given the post-mitotic status of myofibers and stable expression of plasmid DNA, we believe this method will reduce biological variability in animal studies by allowing longitudinal studies of the same animal cohort.
KeywordsMicroRNA In vivo imaging Hydrodynamic limb vein injection Plasmid DNA Reporter assay Gene therapy Muscular dystrophy Luciferase Bioluminescence
Skeletal muscle displays a remarkable ability to remodel in response to pathologic and physiologic stimuli ([1–3] and reviewed in ). How changes in gene expression mediate these processes by post-transcriptional regulation has been heavily studied in the context of diseased, hypertrophic, and regenerating skeletal muscle [5–7]. While recent studies have greatly enhanced our understanding of these dynamic processes, measuring post-transcriptional changes that occur in vivo is challenging and this has limited the experimental avenues available. Additionally, the discovery of post-transcriptional regulation by microRNAs (miRNAs) in skeletal muscle has increased the complexity of these processes.
miRNAs are a type of short, non-coding RNA that post-transcriptionally regulate gene expression. miRNAs function by guiding the RNA-induced silencing complex (RISC) to target mRNAs, dictated by base pairing to target sites primarily in their 3′-untranslated regions (UTRs). miRNAs can downregulate the expression of several to hundreds of target genes by repressing translation and/or destabilizing target mRNAs [8, 9]. miRNAs are required for normal skeletal muscle development in mice , and several miRNAs have been shown to be dynamically regulated during hypertrophy , acute exercise , regeneration after injury , and in the remodeling that occurs in response to genetic muscle disease [14–17]. In particular, miR-206 is expressed specifically in skeletal muscle, and is highly expressed in regenerating fibers . miR-206 has been shown to promote terminal differentiation of myoblasts by regulating the expression of genes including connexin43 , utrophin , pax3 , pax7  and DNA polymerase α . Many of these studies rely on data obtained from transgenic mouse studies, and ex vivo sample analysis - both currently invaluable to the study of miRNAs. The study of miRNA regulation in skeletal muscle, however, would benefit from a system that enabled rapid, reproducible, longitudinal in vivo reporter assays, at a fraction of the cost of transgenic mouse production and analysis, and with fewer animals needed than for ex vivo studies.
Several studies have shown that stable gene expression can be achieved in post-mitotic myofibers in vivo by the introduction of plasmid DNA (pDNA) [23–26]. Unlike viral DNA vectors, pDNA is non-immunogenic , easily manipulated, and relatively inexpensive to produce. Methods for introducing naked pDNA into myofibers include intramuscular injection , electroporation [26, 27], and more recently, hydrodynamic limb vein (HLV) injection [28, 29]. While these methods all result in efficient myofiber transduction, only HLV injection is minimally damaging to the muscle , enabling studies of muscle remodeling to take place in the absence of widespread myofiber regeneration. Moreover, HLV injection results in more widespread pDNA distribution than intramuscular injection or electroporation, which are limited to the site of injection, or single muscle groups, respectively [24, 26].
In vivo bioluminescent and fluorescent imaging (BLI) of genetically encoded reporters has been a useful tool in murine xenograft studies including cancer , chondrogenic differentiation , viral infection , and even in studies of miRNA biogenesis and post-transcriptional regulation [34, 35]. All of these studies, however, have relied on the expression of reporter genes in cells cultured in vitro, and none have demonstrated the ability to quantify skeletal muscle reporter gene expression in situ. We therefore developed a novel system using HLV injection of reporter pDNA into skeletal muscle in combination with in vivo BLI in order to quantify miRNA activity. Before testing, we anticipated that animal-to-animal variation in injection efficiency would confound true changes in reporter expression. While several groups have reported the utility of Renilla luciferases as a normalizer in in vivo reporter studies [32, 36], we found that the fast kinetics and requirement for intravenous substrate delivery made this approach technically challenging. To solve this problem, we employed a dual-reporter approach consisting of a high-efficiency click-beetle luciferase from Pyrophorus plagiophthalamus (CBG99) , and the far-red fluorescent protein mKATE  for signal normalization. mKATE has been shown to have a maximum emission wavelength (635 nm) that is optimal for tissue penetration, and to have high pH and photostability, making this an ideal protein for in vivo BLI.
As a proof of principle, we measured miR-206 activity and show that the activity measured using this technique reproduces the levels obtained from quantitative reverse transcription PCR (qRT-PCR) measurements. We believe this technique will prove useful not only in the quantification of real-time miRNA activity, but also in studies of transcriptional and post-transcriptional regulation.
Two perfectly complementary miR-206 [NCBI:NR_029593] binding sites were inserted between the Xba1 and Fse1 restriction sites downstream of the CBG99 stop codon in pCBG99-Control (Promega, Madison, WI, USA) using the following oligonucleotide sequences: 5′-CTAGACCACACACTTCCTTACATTCCAAAACCACACACTTCCTTACATTCCAGGCCGG, and 5′-CCTGGAATGTAAGGAAGTGTGTGGTTTTGGAATGTAAGGAAGT GTGTGGT. pcDNA-mKATE was a kind gift from Amy Palmer (University of Colorado at Boulder, Boulder, CO, USA), and pCMV-eGFP from Stephen Langer (University of Colorado at Boulder, Boulder, CO, USA).
Hydrodynamic limb vein injection
All animal experiments were performed using protocols approved by University of Colorado and Colorado State University Institutional Animal Care and Use Committees (IACUC). Mice were injected according to a protocol modified from Hagstrom, et al. . Briefly, after sedation with 1 to 4% inhaled isoflurane, a tourniquet was secured around the upper hindlimb to restrict blood flow for 1 to 2 minutes prior to injection, and 2 minutes after injection. The hindlimb was first cleaned with 70% ethanol, and an incision was made with surgical scissors on the medial surface of the leg to expose the great saphenous vein. A ½ inch 30-gauge needle connected by catheter to a syringe was then inserted in an anterograde direction into the vein. Endotoxin-free pDNA isolated using Endofree® Plasmid Maxi Kit (Qiagen, Hilden, Germany) and diluted in sterile saline solution (volume determined according to the formula: 1 + (((body weight in grams − 25)/25) × 1/2)mL), was delivered at a rate of 7 mL/minute by a programmable syringe pump (KD Scientific, Holliston, MA, USA). Two minutes after the injection was completed, the tourniquet was released and the incision was closed with nonabsorbable 6–0 silk suture (Davis-Geck, Brooklyn, NY, USA). Mice recovered on a 37°C heat block and were monitored for adverse effects.
Barium chloride injury
To induce muscle degeneration, mice were first anesthetized with 1 to 4% inhaled isoflurane, and the right hindlimb was shaved. After cleaning the area with 70% ethanol, the right gastrocnemius was injected with 50 μL of a 1.2% barium chloride solution in normal saline using a 27-gauge insulin syringe. Mice recovered on a 37°C heat block and were monitored for adverse effects.
In vivo bioluminescent and fluorescent imaging
Animals were anesthetized using 1 to 4% isoflurane prior to imaging and placed in the chamber of an IVIS 100 in vivo imaging system (Caliper Biosciences, Hopkinton, MA, USA) housed at Colorado State University’s Animal Cancer Center (Fort Collins, CO, USA). The mKATE fluorescent signal was then collected using sequential mode with a 1-s exposure time and the Cy5.5 excitation/emission filter set. Animals were then removed from the imaging chamber and injected intraperitoneally with 200 μL of 30 mg/mL D-luciferin. Ten minutes after substrate injection, bioluminescent signal was collected for 1 minute using the open filter mode. Images were analyzed using LivingImage software (Caliper Biosciences) and photons/sec/cm2/steradian were quantified using region-of-interest (ROI) analysis. Mice recovered from anesthesia on a 37°C heat block.
Muscles for immunofluorescence were frozen in liquid nitrogen-cooled isopentane and mounted in optimal cutting temperature (OCT) medium (Sakura Finetek, Torrance, CA, USA). Cryosections (12 μm thick) were fixed in 4% paraformaldehyde for 10 minutes at room temperature, then blocked for 1 hour with 5% goat serum in PBS and 0.1% Triton X-100. Following blocking, sections were stained with anti-laminin at 1:500 (L-9393, Sigma, St. Louis, MO, USA) or anti-desmin at 1:20 (D-8281, Sigma) overnight at 4°C. After washing several times in PBS with 0.1% Triton X-100, anti-rabbit Texas red secondary antibody was applied at 1:100 dilution for 1 hour at 37°C (711-075-152, Jackson, West Grove, PA, USA). After washing again in PBS with 0.1% Triton X-100, sections were counterstained with 300 nM 4′,6-diamidino-2-phenylindole (DAPI) for 5 minutes at room temperature (Sigma D-9542), and mounted using Fluoromount G (Southern Biotech, Birmingham, AL, USA).
Quantification of injection efficiency
To determine HLV injection efficiency, percentages of GFP-positive fibers were quantified using immunofluorescence on lower hindlimb sections from pCMV-eGFP-injected animals. Following imaging on an inverted epifluorescent microscope (Eclipse TE2000, Nikon, Melville, NY, USA), GFP, laminin, and DAPI images were merged to produce a composite (ImageJ software, National Institutes of Health, Bethesda, MD, USA). GFP-positive fibers were counted when GFP signal across a myofiber was greater than background levels. Total fiber number was counted using laminin staining to demarcate fiber boundaries. Percentages are reported as an average of GFP-positive fibers for ten fields of view for the gastrocnemius, and five fields each for the soleus and tibialis anterior (TA).
To measure miRNA expression, total RNA was first isolated from snap-frozen skeletal muscles using TRI reagent (Molecular Research Center, Cincinnati, OH, USA). Then, 7 ng of total RNA per reaction was reverse-transcribed and PCR-amplified on a CFX96 thermocycler (Bio-Rad, Hercules, CA, USA) using Taqman miRNA assays (Invitrogen, Grand Island, NY, USA). Relative miRNA expression was determined using the 2-ΔΔCt method , using sno202 as a reference gene.
For qRT-PCR experiments, relative miR-206 expression values were compared to controls (for assessment of muscle damage, controls were uninjured/uninjected contralateral limbs for each time point, and for miR-206 reporter measurements, controls were C57Bl/6 animals) using the unpaired Student’s t- test. For BLI measurements, statistics were performed by comparing mean normalized photons/s/cm2/steradian (CBG99/mKATE) of pCBG99-2x-miR-206-injected hindlimbs, to mean normalized photons/s/cm2/steradian of pCBG99-Control-injected hindlimbs for mdx4cv and C57Bl/6 animals using the unpaired Student’s t-test.
HLV injection does not induce myofiber regeneration
Reporter expression is well distributed and is quantifiable using in vivo imaging
miRNA activity measurements are consistent with miRNA qRT-PCR measurements
Several groups have reported the safety and efficacy of pDNA injections using HLV for gene therapy approaches [23, 28, 29]. We found this technique also to be useful in studies requiring minimally damaging introduction of genetically encoded reporters into skeletal muscle and have used it in combination with BLI and ROI analysis to analyze Myh7b promoter activity in vivo. We also found that this technique induces minimal muscle regeneration as assessed by miR-206 induction, and to our knowledge this is the first report of using an in vivo transfection method that does not induce myofiber regeneration for luciferase reporter studies.
The distribution of GFP-positive myofibers after HLV injection that we have seen is similar to that reported by Wooddell, et al.  although the percentage of transfected fibers we report is lower. This may be due to decreased sensitivity of detecting a fluorescent reporter (GFP) versus a colorimetric stain (β-galactosidase). Similar to this report, we find the highest percentage (15.9%) of transfected myofibers in the posterior lower leg (gastrocnemius) muscles and the lowest percentage (6.1%) in the anterior lower leg (TA) muscles (Figure 3). Additionally, others have observed reporter gene expression up to 49 weeks after HLV injection , suggesting that this method could be used for longer-term regulatory studies, provided that the luciferase and mKATE signals follow similar expression profiles.
In summary, HLV injection of pDNA reporters into skeletal muscle followed by BLI is a useful technique for studies of gene regulation. Here, we show that it is possible to measure miRNA activity in myofibers in situ, without activation of a regeneration response. This technique has the added benefit of reducing the cost associated with producing transgenic animals for skeletal muscle studies, and will likely allow reduced animal numbers and decreased variability in future experiments by enabling longitudinal studies of the same animal cohort.
Bioluminescent and fluorescent imaging
Green fluorescent protein
hydrodynamic limb vein
Optimum cutting temperature
Quantitative reverse transcription polymerase chain reaction
RNA-induced silencing complex
Region of interest
We would like to thank Mark Noble for assistance with HLV injection, Adam Chicco for assistance with animal protocols, and Margaret Isenhart for animal care. This work was funded by NIH R01GM029090 to LL and NIH 5T32GM007135-36 to MG.
- Porter JD, Khanna S, Kaminski HJ, Rao JS, Merriam AP, Richmonds CR, Leahy P, Li J, Guo W, Andrade FH: A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice. Hum Mol Genet. 2002, 11: 263-272. 10.1093/hmg/11.3.263.View ArticlePubMedGoogle Scholar
- Haddad F, Herrick RE, Adams GR, Baldwin KM: Myosin heavy chain expression in rodent skeletal muscle: effects of exposure to zero gravity. J Appl Physiol. 1993, 75: 2471-2477.PubMedGoogle Scholar
- Daugaard JR, Nielsen JN, Kristiansen S, Andersen JL, Hargreaves M, Richter EA: Fiber type-specific expression of GLUT4 in human skeletal muscle: influence of exercise training. Diabetes. 2000, 49: 1092-1095. 10.2337/diabetes.49.7.1092.View ArticlePubMedGoogle Scholar
- Bassel-Duby R, Olson EN: Signaling pathways in skeletal muscle remodeling. Annu Rev Biochem. 2006, 75: 19-37. 10.1146/annurev.biochem.75.103004.142622.View ArticlePubMedGoogle Scholar
- Farina NH, Hausburg M, Dalla Betta N, Pulliam C, Srivastava D, Cornelison DD, Olwin BB: A role for RNA post-transcriptional regulation in satellite cell activation. Skeletal Muscle. 2012, 2: 1-10.1186/2044-5040-2-1.View ArticleGoogle Scholar
- Mahadevan M, Tsilfidis C, Sabourin L, Shutler G, Amemiya C, Jansen G, Neville C, Narang M, Barceló J, O’Hoy K: Myotonic dystrophy mutation: an unstable CTG repeat in the 3′ untranslated region of the gene. Science. 1992, 255: 1253-1255. 10.1126/science.1546325.View ArticlePubMedGoogle Scholar
- Cesana M, Cacchiarelli D, Legnini I, Santini T, Sthandier O, Chinappi M, Tramontano A, Bozzoni I: A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell. 2011, 147: 358-369. 10.1016/j.cell.2011.09.028.PubMed CentralView ArticlePubMedGoogle Scholar
- Djuranovic S, Nahvi A, Green R: MiRNA-mediated gene silencing by translational repression followed by mRNA deadenylation and decay. Science. 2012, 336: 237-240. 10.1126/science.1215691.PubMed CentralView ArticlePubMedGoogle Scholar
- Bazzini AA, Lee MT, Giraldez AJ: Ribosome profiling shows that miR-430 reduces translation before causing mRNA decay in zebrafish. Science. 2012, 336: 233-237. 10.1126/science.1215704.PubMed CentralView ArticlePubMedGoogle Scholar
- O’Rourke JR, Georges SA, Seay HR, Tapscott SJ, McManus MT, Goldhamer DJ, Swanson MS, Harfe BD: Essential role for Dicer during skeletal muscle development. Dev Biol. 2007, 311: 359-368. 10.1016/j.ydbio.2007.08.032.PubMed CentralView ArticlePubMedGoogle Scholar
- McCarthy JJ, Esser KA: MicroRNA-1 and microRNA-133a expression are decreased during skeletal muscle hypertrophy. J Appl Physiol. 2007, 102: 306-313.View ArticlePubMedGoogle Scholar
- Safdar A, Abadi A, Akhtar M, Hettinga BP, Tarnopolsky MA, Lucia A: miRNA in the regulation of skeletal muscle adaptation to acute endurance exercise in C57Bl/6J male mice. PLoS One. 2009, 4: e5610-e5610. 10.1371/journal.pone.0005610.PubMed CentralView ArticlePubMedGoogle Scholar
- Yuasa K, Hagiwara Y, Ando M, Nakamura A, Takeda S, Hijikata T: MicroRNA-206 is highly expressed in newly formed muscle fibers: implications regarding potential for muscle regeneration and maturation in muscular dystrophy. Cell Struct Funct. 2008, 33: 163-169. 10.1247/csf.08022.View ArticlePubMedGoogle Scholar
- McCarthy JJ, Esser KA, Andrade FH: MicroRNA-206 is overexpressed in the diaphragm but not the hindlimb muscle of mdx mouse. Am J Physiol Cell Physiol. 2007, 293: C451-C457. 10.1152/ajpcell.00077.2007.View ArticlePubMedGoogle Scholar
- Liu N, Williams AH, Maxeiner JM, Bezprozvannaya S, Shelton JM, Richardson JA, Bassel-Duby R, Olson EN: microRNA-206 promotes skeletal muscle regeneration and delays progression of Duchenne muscular dystrophy in mice. J Clin Invest. 2012, 122: 2054-2065. 10.1172/JCI62656.PubMed CentralView ArticlePubMedGoogle Scholar
- Eisenberg I, Eran A, Nishino I, Moggio M, Lamperti C, Amato AA, Lidov HG, Kang PB, North KN, Mitrani-Rosenbaum S, Flanigan KM, Neely LA, Whitney D, Beggs AH, Kohane IS, Kunkel LM: Distinctive patterns of microRNA expression in primary muscular disorders. Proc Natl Acad Sci USA. 2007, 104: 17016-17021. 10.1073/pnas.0708115104.PubMed CentralView ArticlePubMedGoogle Scholar
- Gambardella S, Rinaldi F, Lepore SM, Viola A, Loro E, Angelini C, Vergani L, Novelli G, Botta A: Overexpression of microRNA-206 in the skeletal muscle from myotonic dystrophy type 1 patients. J Transl Med. 2010, 8: 48-10.1186/1479-5876-8-48.PubMed CentralView ArticlePubMedGoogle Scholar
- Anderson C, Catoe H, Werner R: MIR-206 regulates connexin43 expression during skeletal muscle development. Nucleic Acids Res. 2006, 34: 5863-5871. 10.1093/nar/gkl743.PubMed CentralView ArticlePubMedGoogle Scholar
- Rosenberg MI, Georges SA, Asawachaicharn A, Analau E, Tapscott SJ: MyoD inhibits Fstl1 and Utrn expression by inducing transcription of miR-206. J Cell Biol. 2006, 175: 77-85. 10.1083/jcb.200603039.PubMed CentralView ArticlePubMedGoogle Scholar
- Boutet SC, Cheung TH, Quach NL, Liu L, Prescott SL, Edalati A, Iori K, Rando TA: Alternative polyadenylation mediates microRNA regulation of muscle stem cell function. Cell Stem Cell. 2012, 10: 327-336. 10.1016/j.stem.2012.01.017.PubMed CentralView ArticlePubMedGoogle Scholar
- Dey BK, Gagan J, Dutta A: MiR-206 and −486 induce myoblast differentiation by downregulating Pax7. Mol Cell Biol. 2010, 31: 1-46.Google Scholar
- Kim HK, Lee YS, Sivaprasad U, Malhotra A, Dutta A: Muscle-specific microRNA miR-206 promotes muscle differentiation. J Cell Biol. 2006, 174: 677-687. 10.1083/jcb.200603008.PubMed CentralView ArticlePubMedGoogle Scholar
- Sebestyen MG, Hegge JO, Noble M, Lewis D, Herweijer H, Wolff JA: Progress toward a non-viral gene therapy protocol for the treatment of anemia. Hum Gene Ther. 2007, 18: 269-285. 10.1089/hum.2006.186.PubMed CentralView ArticlePubMedGoogle Scholar
- Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL: Direct gene transfer into mouse muscle in vivo. Science. 1990, 247: 1465-1468. 10.1126/science.1690918.View ArticlePubMedGoogle Scholar
- Fabre EE, Bigey P, Orsini C, Scherman D: Comparison of promoter region constructs for in vivo intramuscular expression. J Gene Med. 2006, 8: 636-645. 10.1002/jgm.878.View ArticlePubMedGoogle Scholar
- Aihara H, Miyazaki J-I: Gene transfer into muscle by electroporation in vivo. Nat Biotechnol. 1998, 16: 867-870. 10.1038/nbt0998-867.View ArticlePubMedGoogle Scholar
- Deleuze V, Scherman D, Bureau MF: Interleukin-10 expression after intramuscular DNA electrotransfer: kinetic studies. Biochem Biophys Res Commun. 2002, 299: 29-34. 10.1016/S0006-291X(02)02580-9.View ArticlePubMedGoogle Scholar
- Suda T, Liu D: Hydrodynamic gene delivery: its principles and applications. Mol Ther. 2007, 15: 2063-2069. 10.1038/sj.mt.6300314.View ArticlePubMedGoogle Scholar
- Hagstrom JE, Hegge J, Zhang G, Noble M, Budker V, Lewis DL, Herweijer H, Wolff JA: A facile nonviral method for delivering genes and siRNAs to skeletal muscle of mammalian limbs. Mol Ther. 2004, 10: 386-398. 10.1016/j.ymthe.2004.05.004.View ArticlePubMedGoogle Scholar
- Toumi H, Hegge J, Subbotin V, Noble M, Herweijer H, Best TM, Hagstrom JE: Rapid intravascular injection into limb skeletal muscle: a damage assessment study. Mol Ther. 2006, 13: 229-236. 10.1016/j.ymthe.2005.07.699.View ArticlePubMedGoogle Scholar
- Kim HJ, Chung J-K, Hwang DW, Lee DS, Kim S: In vivo imaging of miR-221 biogenesis in papillary thyroid carcinoma. Mol Imaging Biol. 2009, 11: 71-78. 10.1007/s11307-008-0188-6.View ArticlePubMedGoogle Scholar
- Vilalta M, Jorgensen C, Degano IR, Chernajovsky Y, Gould D, Noel D, Andrades JA, Becerra J, Rubio N, Blanco J: Dual luciferase labelling for non-invasive bioluminescence imaging of mesenchymal stromal cell chondrogenic differentiation in demineralized bone matrix scaffolds. Biomaterials. 2009, 30: 4986-4995. 10.1016/j.biomaterials.2009.05.056.View ArticlePubMedGoogle Scholar
- Luker KEK, Luker GDG: Applications of bioluminescence imaging to antiviral research and therapy: multiple luciferase enzymes and quantitation. Antiviral Res. 2008, 78: 9-9. 10.1016/j.antiviral.2008.01.004.View ArticleGoogle Scholar
- Lee JY, Kim S, Hwang DW, Jeong JM, Chung J-K, Lee MC, Lee DS: Development of a dual-luciferase reporter system for in vivo visualization of MicroRNA biogenesis and posttranscriptional regulation. J Nucl Med. 2008, 49: 285-294. 10.2967/jnumed.107.042507.View ArticlePubMedGoogle Scholar
- Kim S, Hwang DW, Lee DS: A study of microRNAsin silicoandin vivo: bioimaging of microRNA biogenesis and regulation. FEBS J. 2009, 276: 2165-2174. 10.1111/j.1742-4658.2009.06935.x.View ArticlePubMedGoogle Scholar
- Bhaumik S, Gambhir SS: Optical imaging of Renilla luciferase reporter gene expression in living mice. Proc Natl Acad Sci USA. 2002, 99: 377-382. 10.1073/pnas.012611099.PubMed CentralView ArticlePubMedGoogle Scholar
- Miloud T, Henrich C, Hämmerling GJ: Quantitative comparison of click beetle and firefly luciferases for in vivo bioluminescence imaging. J Biomed Opt. 2007, 12: 054018-10.1117/1.2800386.View ArticlePubMedGoogle Scholar
- Shcherbo D, Merzlyak EM, Chepurnykh TV, Fradkov AF, Ermakova GV, Solovieva EA, Lukyanov KA, Bogdanova EA, Zaraisky AG, Lukyanov S, Chudakov DM: Bright far-red fluorescent protein for whole-body imaging. Nat Methods. 2007, 4: 741-746. 10.1038/nmeth1083.View ArticlePubMedGoogle Scholar
- Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 2001, 25: 402-408. 10.1006/meth.2001.1262.View ArticlePubMedGoogle Scholar
- Yeung F, Chung E, Guess MG, Bell ML, Leinwand LA: Myh7b/miR-499 gene expression is transcriptionally regulated by MRFs and Eos. Nucleic Acids Res. 2012, 40: 7303-7318. 10.1093/nar/gks466.PubMed CentralView ArticlePubMedGoogle Scholar
- Wooddell CI, Hegge JO, Zhang G, Sebestyén MG, Noble M, Griffin JB, Pfannes LV, Herweijer H, Hagstrom JE, Braun S, Huss T, Wolff JA: Dose response in rodents and nonhuman primates after hydrodynamic limb vein delivery of naked plasmid DNA. Hum Gene Ther. 2011, 22: 889-903. 10.1089/hum.2010.160.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.